Table 1.
Baseline demographics and clinical characteristics of cis-gender Ugandan female participants with HIV on efavirenz 600mg-based ART who received double-dose LNG implant (300LNG+ART) and participants without HIV who received standard-dose LNG implant (150LNG).
| Characteristic | 300LNG + ART n=27 |
150LNG n=19 |
P value |
|---|---|---|---|
|
| |||
| Age in years | 34.0 (28.0–40.5) | 33.0 (30.0–34.5) | 0.35 |
| Weight, kga | 61.0 (49.8–66.0) | 64.9 (59.0–74.5) | <0.05 |
| BMI, kg/m2a | 23.1 (20.9–25.1) | 26.5 (23.4–29.9) | 0.02 |
| SHBG, nmol/La | 135.2 (88.0–170.4) b | 54.8 (40.8–89.3) | <0.001 |
| Cohabitating or married | 18 (66.6) | 12 (63.2) | 1.00 |
| Prior live births | 4.0 (2.0–4.0) | 3.0 (2.0–3.5) | 0.27 |
| CD4 cell count, cells/microliter | 649 (475–846) | NA | - |
| HIV-1 RNA <50 copies/mLa | 27 (100%) | NA | - |
| Efavirenz-based ART duration, monthsa | 44 (28–51) | NA | - |
Continuous data presented as median (interquartile range); categorical data presented as n (%).
ART = antiretroviral therapy; BMI = body mass index; LNG = levonorgestrel; NA = not applicable; SHBG = sex hormone binding globulin
All data were collected at screening, unless indicated. Body weight, and BMI, SHBG, CD4 count, and ART duration were measured or assessed at enrollment.
n=22; 5 (of 27) participants in the 300LNG + ART group had baseline SHBG concentrations >250 nmol/L, the assay upper limit of quantification, and were excluded from the SHBG summary statistics.